Pseudoexon activation increases phenotype severity in a Becker muscular dystrophy patient

被引:23
作者
Greer, Kane [1 ,2 ]
Mizzi, Kayla [2 ]
Rice, Emily [2 ]
Kuster, Lukas [2 ]
Barrero, Roberto A. [1 ]
Bellgard, Matthew I. [1 ]
Lynch, Bryan J. [3 ]
Foley, Aileen Reghan [3 ]
Rathallaigh, Eoin O. [4 ]
Wilton, Steve D. [1 ,2 ,5 ]
Fletcher, Sue [1 ,2 ,5 ]
机构
[1] Murdoch Univ, Ctr Comparat Gen, 90 South St, Murdoch, WA 6150, Australia
[2] Univ Western Australia, Crawley, WA 6009, Australia
[3] Childrens Univ Hosp, Dublin, Ireland
[4] Cent Remedial Clin, Dept Physiotherapy, Dublin, Ireland
[5] Western Australian Neuroscience Inst, Nedlands, WA, Australia
基金
英国医学研究理事会;
关键词
Cryptic splicing; Duchenne/Becker muscular dystrophy; dystrophin; exon splicing enhancer; pseudoexon;
D O I
10.1002/mgg3.144
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
We report a dystrophinopathy patient with an in-frame deletion of DMD exons 45-47, and therefore a genetic diagnosis of Becker muscular dystrophy, who presented with a more severe than expected phenotype. Analysis of the patient DMD mRNA revealed an 82 bp pseudoexon, derived from intron 44, that disrupts the reading frame and is expected to yield a nonfunctional dystrophin. Since the sequence of the pseudoexon and canonical splice sites does not differ from the reference sequence, we concluded that the genomic rearrangement promoted recognition of the pseudoexon, causing a severe dystrophic phenotype. We characterized the deletion breakpoints and identified motifs that might influence selection of the pseudoexon. We concluded that the donor splice site was strengthened by juxtaposition of intron 47, and loss of intron 44 silencer elements, normally located downstream of the pseudoexon donor splice site, further enhanced pseudoexon selection and inclusion in the DMD transcript in this patient.
引用
收藏
页码:320 / 326
页数:7
相关论文
共 26 条
[1]   Antisense Oligonucleotide-Mediated Exon Skipping for Duchenne Muscular Dystrophy: Progress and Challenges [J].
Arechavala-Gomeza, Virginia ;
Anthony, Karen ;
Morgan, Jennifer ;
Muntoni, Francesco .
CURRENT GENE THERAPY, 2012, 12 (03) :152-160
[2]  
BEGGS AH, 1991, AM J HUM GENET, V49, P54
[3]   Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management [J].
Bushby, Katharine ;
Finkel, Richard ;
Birnkrant, David J. ;
Case, Laura E. ;
Clemens, Paula R. ;
Cripe, Linda ;
Kaul, Ajay ;
Kinnett, Kathi ;
McDonald, Craig ;
Pandya, Shree ;
Poysky, James ;
Shapiro, Frederic ;
Tomezsko, Jean ;
Constantin, Carolyn .
LANCET NEUROLOGY, 2010, 9 (01) :77-93
[4]   THE CLINICAL, GENETIC AND DYSTROPHIN CHARACTERISTICS OF BECKER MUSCULAR-DYSTROPHY .2. CORRELATION OF PHENOTYPE WITH GENETIC AND PROTEIN ABNORMALITIES [J].
BUSHBY, KMD ;
GARDNERMEDWIN, D ;
NICHOLSON, LVB ;
JOHNSON, MA ;
HAGGERTY, ID ;
CLEGHORN, NJ ;
HARRIS, JB ;
BHATTACHARYA, SS .
JOURNAL OF NEUROLOGY, 1993, 240 (02) :105-112
[5]   Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study [J].
Cirak, Sebahattin ;
Arechavala-Gomeza, Virginia ;
Guglieri, Michela ;
Feng, Lucy ;
Torelli, Silvia ;
Anthony, Karen ;
Abbs, Stephen ;
Garralda, Maria Elena ;
Bourke, John ;
Wells, Dominic J. ;
Dickson, George ;
Wood, Matthew J. A. ;
Wilton, Steve D. ;
Straub, Volker ;
Kole, Ryszard ;
Shrewsbury, Stephen B. ;
Sewry, Caroline ;
Morgan, Jennifer E. ;
Bushby, Kate ;
Muntoni, Francesco .
LANCET, 2011, 378 (9791) :595-605
[6]  
Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO
[7]  
2-T
[8]  
Dastur RS, 2008, NEUROL INDIA, V56, P374
[9]  
DENDUNNEN JT, 1989, AM J HUM GENET, V45, P835
[10]   Human Splicing Finder: an online bioinformatics tool to predict splicing signals [J].
Desmet, Francois-Olivier ;
Hamroun, Dalil ;
Lalande, Marine ;
Collod-Beroud, Gwenaelle ;
Claustres, Mireille ;
Beroud, Christophe .
NUCLEIC ACIDS RESEARCH, 2009, 37 (09)